<p>尽管已经有了强劲的表现，<strong>Arcutis Biotherapeutics, Inc.</strong>（纳斯达克代码：ARQT）股票仍在继续上涨，过去三十天上涨了 28%。在最新的上涨之后，年增幅达到了 147%，引起了投资者的关注。</p>
<p>尽管价格有了明显的反弹，但你仍然可以理解对 Arcutis Biotherapeutics 的市销率为 12 倍感到无动于衷，因为美国生物科技行业的中位市销率也接近 12.1 倍。虽然这可能不会引起任何人的注意，但如果市销率没有合理的依据，投资者可能会错过潜在的机会或忽视即将到来的失望。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p>查看我们对 Arcutis Biotherapeutics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/549019944-ps-multiple-vs-industry-1-dark-2/1765282375082?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/549019944-ps-multiple-vs-industry-1-dark-2/1765282375082"/></p>
<p>纳斯达克 GS:ARQT 市销率与行业比较 2025 年 12 月 9 日</p>
<h3>Arcutis Biotherapeutics 最近的表现如何？</h3>
<p>最近一段时间，Arcutis Biotherapeutics 的表现并不理想，因为其收入增长速度低于大多数其他公司。一个可能的原因是，市销率适中，因为投资者认为这种乏力的收入表现会有所好转。如果没有，那么现有股东可能会对股价的可持续性感到有些紧张。</p>
<p>如果你想了解分析师对未来的预测，可以查看我们对 Arcutis Biotherapeutics 的 <strong>免费</strong> 报告。</p>
<h2>Arcutis Biotherapeutics 是否有收入增长的预测？</h2>
<p>Arcutis Biotherapeutics 的市销率对于一家预计仅能实现适度增长的公司来说是典型的，重要的是，它的表现与行业保持一致。</p>
<p>回顾过去一年，公司营收实现了 129% 的惊人增长。最近三年期间，收入也经历了令人难以置信的整体增长，这得益于其出色的短期表现。因此，我们可以首先确认公司在这段时间内在收入增长方面做得非常出色。</p>
<p>展望未来，覆盖该公司的八位分析师的估计显示，未来三年收入预计将以每年 32% 的速度增长。这一增速明显低于更广泛行业的 130% 的年增长预测。</p>
<p>根据这些信息，我们发现 Arcutis Biotherapeutics 的市销率与行业相对接近，这很有趣。似乎大多数投资者忽视了相对有限的增长预期，并愿意为接触该股票支付更高的价格。如果市销率降至与增长前景更为一致的水平，这些股东可能会为未来的失望埋下伏笔。</p>
<h2>Arcutis Biotherapeutics 的市销率对投资者意味着什么？</h2>
<p>Arcutis Biotherapeutics 似乎重新受到青睐，价格大幅上涨使其市销率回归到行业其他公司的水平。然而，仅仅依靠市销率来判断是否应该出售你的股票并不明智，但它可以作为公司未来前景的实用指南。</p>
<p>鉴于 Arcutis Biotherapeutics 的收入增长预测相对温和，与更广泛的行业相比，看到其以当前市销率交易令人感到惊讶。目前，我们对市销率并不乐观，因为预测的未来收入不太可能长期支持更积极的市场情绪。这样的情况对当前和潜在投资者构成风险，如果低收入增长影响市场情绪，股价可能会下跌。</p>
<p>我们不想过于泼冷水，但我们确实发现了 <strong>1 个需要注意的警告信号</strong>，关于 Arcutis Biotherapeutics。</p>
<p>如果这些 <strong>风险让你重新考虑对 Arcutis Biotherapeutics 的看法</strong>，请查看我们的高质量股票互动列表，以了解还有哪些其他选择。</p>

ARQT

<p>Arcutis Biotherapeutics, Inc.（纳斯达克代码：ARQT）股票在过去 30 天内上涨了 28%，使其年增幅达到 147%。尽管价格上涨，其市销率为 12 倍，与生物科技行业平均水平相符。分析师预测未来三年的年收入增长率为 32%，低于行业的 130%。如果增长预期未能实现，投资者可能会感到失望，因为当前的市销率可能无法持续</p>

<p>Despite an already strong run, <strong>Arcutis Biotherapeutics, Inc.</strong> (NASDAQ:ARQT) shares have been powering on, with a gain of 28% in the last thirty days. The annual gain comes to 147% following the latest surge, making investors sit up and take notice.</p>
<div class="lb-trans"><p>尽管已经有了强劲的表现，<strong>Arcutis Biotherapeutics, Inc.</strong>（纳斯达克代码：ARQT）股票仍在继续上涨，过去三十天上涨了 28%。在最新的上涨之后，年增幅达到了 147%，引起了投资者的关注。</p>
</div><p>In spite of the firm bounce in price, you could still be forgiven for feeling indifferent about Arcutis Biotherapeutics' P/S ratio of 12x, since the median price-to-sales (or &#34;P/S&#34;) ratio for the Biotechs industry in the United States is also close to 12.1x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.</p>
<div class="lb-trans"><p>尽管价格有了明显的反弹，但你仍然可以理解对 Arcutis Biotherapeutics 的市销率为 12 倍感到无动于衷，因为美国生物科技行业的中位市销率也接近 12.1 倍。虽然这可能不会引起任何人的注意，但如果市销率没有合理的依据，投资者可能会错过潜在的机会或忽视即将到来的失望。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p>Check out our latest analysis for Arcutis Biotherapeutics</p>
<div class="lb-trans"><p>查看我们对 Arcutis Biotherapeutics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/549019944-ps-multiple-vs-industry-1-dark-2/1765282375082" alt="" original-src="https://images.simplywall.st/asset/chart/549019944-ps-multiple-vs-industry-1-dark-2/1765282375082"/></p>
<p>NasdaqGS:ARQT Price to Sales Ratio vs Industry December 9th 2025</p>
<div class="lb-trans"><p>纳斯达克 GS:ARQT 市销率与行业比较 2025 年 12 月 9 日</p>
</div><h3>How Has Arcutis Biotherapeutics Performed Recently?</h3>
<div class="lb-trans"><h3>Arcutis Biotherapeutics 最近的表现如何？</h3>
</div><p>Recent times haven't been great for Arcutis Biotherapeutics as its revenue has been rising slower than most other companies. One possibility is that the P/S ratio is moderate because investors think this lacklustre revenue performance will turn around. If not, then existing shareholders may be a little nervous about the viability of the share price.</p>
<div class="lb-trans"><p>最近一段时间，Arcutis Biotherapeutics 的表现并不理想，因为其收入增长速度低于大多数其他公司。一个可能的原因是，市销率适中，因为投资者认为这种乏力的收入表现会有所好转。如果没有，那么现有股东可能会对股价的可持续性感到有些紧张。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Arcutis Biotherapeutics.</p>
<div class="lb-trans"><p>如果你想了解分析师对未来的预测，可以查看我们对 Arcutis Biotherapeutics 的 <strong>免费</strong> 报告。</p>
</div><h2>Is There Some Revenue Growth Forecasted For Arcutis Biotherapeutics?</h2>
<div class="lb-trans"><h2>Arcutis Biotherapeutics 是否有收入增长的预测？</h2>
</div><p>Arcutis Biotherapeutics' P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.</p>
<div class="lb-trans"><p>Arcutis Biotherapeutics 的市销率对于一家预计仅能实现适度增长的公司来说是典型的，重要的是，它的表现与行业保持一致。</p>
</div><p>Retrospectively, the last year delivered an exceptional 129% gain to the company's top line. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. So we can start by confirming that the company has done a tremendous job of growing revenue over that time.</p>
<div class="lb-trans"><p>回顾过去一年，公司营收实现了 129% 的惊人增长。最近三年期间，收入也经历了令人难以置信的整体增长，这得益于其出色的短期表现。因此，我们可以首先确认公司在这段时间内在收入增长方面做得非常出色。</p>
</div><p>Shifting to the future, estimates from the eight analysts covering the company suggest revenue should grow by 32% per annum over the next three years. That's shaping up to be materially lower than the 130% per year growth forecast for the broader industry.</p>
<div class="lb-trans"><p>展望未来，覆盖该公司的八位分析师的估计显示，未来三年收入预计将以每年 32% 的速度增长。这一增速明显低于更广泛行业的 130% 的年增长预测。</p>
</div><p>With this information, we find it interesting that Arcutis Biotherapeutics is trading at a fairly similar P/S compared to the industry. It seems most investors are ignoring the fairly limited growth expectations and are willing to pay up for exposure to the stock. These shareholders may be setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook.</p>
<div class="lb-trans"><p>根据这些信息，我们发现 Arcutis Biotherapeutics 的市销率与行业相对接近，这很有趣。似乎大多数投资者忽视了相对有限的增长预期，并愿意为接触该股票支付更高的价格。如果市销率降至与增长前景更为一致的水平，这些股东可能会为未来的失望埋下伏笔。</p>
</div><h2>What Does Arcutis Biotherapeutics' P/S Mean For Investors?</h2>
<div class="lb-trans"><h2>Arcutis Biotherapeutics 的市销率对投资者意味着什么？</h2>
</div><p>Arcutis Biotherapeutics appears to be back in favour with a solid price jump bringing its P/S back in line with other companies in the industry Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.</p>
<div class="lb-trans"><p>Arcutis Biotherapeutics 似乎重新受到青睐，价格大幅上涨使其市销率回归到行业其他公司的水平。然而，仅仅依靠市销率来判断是否应该出售你的股票并不明智，但它可以作为公司未来前景的实用指南。</p>
</div><p>Given that Arcutis Biotherapeutics' revenue growth projections are relatively subdued in comparison to the wider industry, it comes as a surprise to see it trading at its current P/S ratio. At present, we aren't confident in the P/S as the predicted future revenues aren't likely to support a more positive sentiment for long. Circumstances like this present a risk to current and prospective investors who may see share prices fall if the low revenue growth impacts the sentiment.</p>
<div class="lb-trans"><p>鉴于 Arcutis Biotherapeutics 的收入增长预测相对温和，与更广泛的行业相比，看到其以当前市销率交易令人感到惊讶。目前，我们对市销率并不乐观，因为预测的未来收入不太可能长期支持更积极的市场情绪。这样的情况对当前和潜在投资者构成风险，如果低收入增长影响市场情绪，股价可能会下跌。</p>
</div><p>We don't want to rain on the parade too much, but we did also find <strong>1 warning sign for Arcutis Biotherapeutics</strong> that you need to be mindful of.</p>
<div class="lb-trans"><p>我们不想过于泼冷水，但我们确实发现了 <strong>1 个需要注意的警告信号</strong>，关于 Arcutis Biotherapeutics。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Arcutis Biotherapeutics</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果这些 <strong>风险让你重新考虑对 Arcutis Biotherapeutics 的看法</strong>，请查看我们的高质量股票互动列表，以了解还有哪些其他选择。</p>
</div>

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) 的股票上涨了 28%，因为投资者的悲观情绪比预期要低